Advertisement Pharmaceutical Business review - Page 294 of 5259 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 2, 2026

CIRM unveils RAPID funding programme for rare diseases

The California Institute for Regenerative Medicine (CIRM) in the US has approved the Rare Disease Acceleration Platform and Innovation and Delivery (RAPID) funding programme, setting aside $100m over two years.

RAPID builds on CIRM’s previous work, including a recent genetic therapy developed within six months for CPS1 deficiency. Credit: warut pothikit / Shutterstock.com.